CH596191A5 - Anti-bacterial benzyl-pyrimidines - Google Patents
Anti-bacterial benzyl-pyrimidinesInfo
- Publication number
- CH596191A5 CH596191A5 CH742676A CH742676A CH596191A5 CH 596191 A5 CH596191 A5 CH 596191A5 CH 742676 A CH742676 A CH 742676A CH 742676 A CH742676 A CH 742676A CH 596191 A5 CH596191 A5 CH 596191A5
- Authority
- CH
- Switzerland
- Prior art keywords
- acid
- compounds
- solution
- bacterial
- pyrimidines
- Prior art date
Links
- OOLOAWZLPBDRJQ-UHFFFAOYSA-N 2-benzylpyrimidine Chemical class N=1C=CC=NC=1CC1=CC=CC=C1 OOLOAWZLPBDRJQ-UHFFFAOYSA-N 0.000 title abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229960005404 sulfamethoxazole Drugs 0.000 description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- -1 are used Chemical compound 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DMZKZOINHKXBDE-UHFFFAOYSA-N methyl 4-formyl-2,6-dimethoxybenzoate Chemical compound COC(=O)C1=C(OC)C=C(C=O)C=C1OC DMZKZOINHKXBDE-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OVTXMXLGPQUKGY-UHFFFAOYSA-N 3,5-dimethoxy-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=C(OC)C=C(C(O)=O)C=C1OC OVTXMXLGPQUKGY-UHFFFAOYSA-N 0.000 description 1
- WXVKGHVDWWXBJX-UHFFFAOYSA-N 3-morpholin-4-ylpropanenitrile Chemical compound N#CCCN1CCOCC1 WXVKGHVDWWXBJX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- JADFCQKRKICRKI-UHFFFAOYSA-N quinoline;sulfane Chemical compound S.N1=CC=CC2=CC=CC=C21 JADFCQKRKICRKI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229950003874 sulfamonomethoxine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Anti-bacterial benzyl-pyrimidines esp powerful in combination with sulphonamides
Description
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen Benzylpyrimidinen der allgemeinen Formel
EMI1.1
worin R1 und R2 C1-Alkyl oder r-Alkenyl bedeuten,
Z ein an eines der Ringstickstoffatome gebundenes Sauerstoffatom darstellt und n = 0 oder 1 ist und von Säureadditionssalzen solcher Verbindungen.
Beispiele von C4-Alkylresten, die geradkettig oder verzweigt sein können, sind Methyl, Äthyl und Propyl. Ein Beispiel einer C2¯3-Alkenylgruppe ist Allyl.
Eine im Rahmen der vorliegenden Erfindung besonders bevorzugte Untergruppe von Verbindungen der Formel I sind diejenigen in denen R1 und R2 Alkyl, insbesondere Methyl oder Äthyl darstellen.
Die Benzylpyrimidine der Formel I und ihre Salze werden erfindungsgemäss dadurch erhalten, dass man in einer Verbindung der Formel
EMI1.2
in der R3 eine Alkylgruppe darstellt und Rt, R2, Z und n die oben angegebenen Bedeutungen besitzen, die.AIkoxycarbonyl- gruppe zur Hydroxymethylgruppe reduziert, und gegebenenfalls eine erhaltene Base in ein Säureadditionssalz überführt.
Die Reduktion einer Alkoxycarbonylgruppe zur Hydroxymethylgruppe kann mit Diisobutylaluminiumhydrid in Dioxan ausgeführt werden.
Die Ausgangsstoffe können, soweit sie nicht bekannt oder im folgenden beschrieben sind, in Analogie zu den nachstehend angegebenen Methoden hergestellt werden.
Für die Herstellung von Säureadditionssalzen, insbesondere von in pharmazeutischen Präparaten brauchbaren Salzen, kommen die üblicherweise für diesen Zweck verwendeten anorganischen Säuren, wie Salzsäure, Schwefelsäure, Phosphorsäure usw. oder organischen Säuren, wie Ameisensäure, Essigsäure, Bernsteinsäure, Milchsäure, Zitronensäure, Maleinsäure, Fumarsäure, Weinsäure, Methansulfonsäure, p-Toluolsulfonsäure usw. in Betracht.
Die Verbindungen der Formel I und ihre Salze sind antibakteriell wirksam. Sie hemmen die bakterielle Dihydrofolat Reduktase und potenzieren die antibakterielle Wirkung von Sulfonamiden, wie z. B. Sulfisoxazol, Sulfadimethoxin, Sulfamethoxazol, 4-Sulfanilamido-5,6-dimethoxy-pyrimidin, 2 Sulfanilamido-4,5-dimethyl-pyrimidin oder Sulfachinoxalin, Sulfadiazin, Sulfamonomethoxin, Isosulfisoxazol und anderen Inhibitoren für Enzyme, die an der Folsäurebiosynthese beteiligt sind, wie z. B. Pteridinderivate.
Für solche Kombinationen einer oder mehrerer der erfindungsgemässen Verbindungen I mit Sulfonamiden kommt in der Humanmedizin orale, rectale und parenterale Applikation in Frage. Das Verhältnis von Verbindung I zu Sulfonamid kann innerhalb eines weiten Bereiches variieren; es beträgt z. B. zwischen 1:40 (Gewichtsteile) und 5:1 (Gewichtsteile); bevorzugte Verhältnisse sind 1:1 bis 1:5.
So kann z. B. eine Tablette 80 mg einer erfindungsgemässen Verbindung I und 400 mg Sulfamethoxazol, eine Kindertablette 20 mg einer erfindungsgemassen Verbindung I und 100 mg Sulfamethoxazol; Sirup (pro 5 ml) 40 mg Verbindung I und 200 mg Sulfamethoxazol enthalten.
Beispiel
Zu einer Lösung von 4,45 g a-(2,4-Diamino-5-pyrimidinyl)2,6-dimethoxy-p-toluylsäuremethylester in 400 ml abs. Dioxan wurden bei 50 C unter Stickstoff und Feuchtigkeitsausschluss 135 ml ca. 15% Diisobutylaluminiumhydrid-Lösung in Dioxan innerhalb von 30 Minuten zugetropft. Die entstandene Suspension wurde 1 Stunde bei 50 C gerührt. Nach Abkühlung auf 30 C wurde als Reaktionsgemisch mit einer Mischung von 25 ml Methanol, 5 ml Wasser und 50 ml Dioxan versetzt und bei 50 C weitere 2 Stunden gerührt. Das feste Material wurde abgetrennt und verworfen. Das Filtrat wurde zur Trockene eingedampft.
Der Rückstand lieferte nach Umkristallisation aus ca. 20 ml Methanol 4-[(2,4-Diamino-5 pyrimidinyl)-methyl]-2,6-dimethoxybenzyl-alkohol vom Smp.
227-228" C.
Das Ausgangsmaterial wurde folgendermassen hergestellt:
Eine Mischung von 271 g 2,6-Dimethoxyterephthalsäure1-mono-methylester, 1,2 1 abs. Benzol, 100 ml Thionylchlorid und 30 ml Dimethylformamid wurde unter Feuchtigkeitsausschluss 2 Stunden am Rückfluss gekocht. Die Lösung wurde im Vakuum zur Trockene eingedampft und der Rückstand 2mal in ca. 100 ml abs. Benzol gelöst und das Lösungsmittel wieder im Vakuum entfernt. Der Rückstand ergab nach Umkristallisieren aus 7 1 heissem n-Heptan 260 g Säurechlorid vom Smp. 100-101 C. Nach Einengen der Mutterlaugen wurden weitere 20 g Säurechlorid (Smp. 90-95"C) erhalten.
40 g Säurechlorid wurden in 400 ml über Natrium getrocknetem Xylol gelöst. Unter Begasung mit N2 wurden 4 g 5 % Pd/BaSO4 und 0,4 ml Chinolin-Schwefel-Regulator zugegeben, die Suspension weitere 10 Minuten mit N2 ausgebla sen und danach wurde unter Rühren bei 110 C Wasserstoff durchgeleitet. Der Verlauf der Reaktion wurde durch Titrieren des entstandenen HCI verfolgt. Nach ca. 2 Stunden (90 % der theoretischen Menge HCI freigesetzt) wurde die Reaktion abgebrochen, die Suspension unter N2 abgekühlt und der Katalysator abgenutscht. Das Filtrat wurde im Vakuum zur Trockene eingeengt, der Rückstand in 150 ml Benzol aufgenommen und mit 500 ml ca. 37 % Natriumbisulfit Lösung 2 Stunden geschüttelt. Die Benzol-Phase wurde abgetrennt und die wässrige Phase mit 100 ml Benzol gewaschen.
Die zurückgebliebene wässrige Lösung wurde auf 5" C abgekühlt und anschliessend mit ca. 20% NaOH-Lösung auf ca.
pH 10 gestellt. Der ausgefallene Aldehyd (und anorganische Salze) wurde abgenutscht. Das feste Material wurde in 400 ml Benzol und 700 ml Wasser aufgenommen, die Benzol-Lösung abgetrennt und die wässerige Phase 2mal mit je 100 ml Benzol extrahiert. Die vereinigten Benzol-Auszüge wurden mit 2 x 50 ml Wasser gewaschen, über MgSO4 getrocknet und im Vakuum zur Trockene eingedampft; 2,6-Dimethoxy-4 formyl-benzoesäuremethylester, Smp. 113-114" C.
Aus einer Lösung von 0,9 g Natrium-Metall in 15 ml abs.
MeOH wurde das Lösungsmittel unter N2 und Feuchtigkeitsausschluss abgedampft. Das zurückgebliebene Natriummethylat wurde in einer Lösung von 25,2 g ss-Morpholinopropionitril in 28 ml über Molekularsieb getrocknetem Dimethylsulfoxid suspendiert und auf 70" C erwärmt. Bei dieser Temperatur wurde eine Lösung von 30 g 2,6-Dimethoxy-4formyl-benzoesäuremethylester in 45 ml wasserfreiem Dimethylsulfoxid innerhalb von 30 Minuten zugetropft und anschliessend 30 Minuten bei 75" C weitergerührt. Nach dieser Zeit konnte praktisch kein Aldehyd mehr nachgewiesen werden. Die Lösung wurde auf + 5" C abgekühlt und tropfenweise mit ca. 30-40 ml Wasser versetzt, angeimpft und ca. 3 Stunden weitergerührt.
Das kristalline Produkt wurde abgenutscht, mit ca. 15 ml auf 0 C abgekühltem Methanol gewaschen und aus Methanol umkristallisiert.
Der 4-(2-Cyano-3-morpholinoallyl)-2,6-dimethoxybenzoe säuremethylester hat einen Smp. von 137-138 C.
8,6 g Anilin wurden unter Kühlung mit 7,6 ml konz. HC1 versetzt. Anschliessend wurden 32 g4-(2-Cyano-3-morpholino allyl)-2,6-dimethoxybenzoesäuremethylester und 100 ml Isopropanol zugegeben. Die Suspension wurde 30 Minuten unter Rühren am Rückfluss erwärmt. Etwa 1/3 bis die Hälfte des Lösungsmittels wurde abgedampft, 20 ml Wasser zugegeben, das kristalline Produkt abgenutscht, mit wenig kaltem Metha nol gewaschen und getrocknet. Umkristallisation aus Methanol lieferte 4-(3 -Anilino-2-cyanoallyl)-2,6-dimethoxybenzoe- säuremethylester vom Smp. 193-194 C.
In einem 2-l-Kolben mit Magnetrührung und Rückflusskühler wurden unter Feuchtigkeitsausschluss 8 g Na-Metall in 200 ml abs. Methanol gelöst.
Zu dieser Lösung wurden 24,7 g Guanidin HC1 zugegeben und die Suspension bei Raumtemperatur 30 Minuten gerührt. Das Natriumchlorid wurde abgenutscht und mit ca.
10 ml kaltem abs. Methanol gewaschen. Das Filtrat wurde mit 46 g 4-(3-Anilino-2-cyanoallyl)-2,6-dimethoxybenzoesäure- methylester und 1000 ml Isopropanol versetzt und die Suspension unter Rühren 50 Stunden am Rückfluss erwärmt. Das Reaktionsgemisch wurde eingeengt, abgekühlt und die ausgefallenen Kristalle abgenutscht.
Nach Kristallisation aus ca. 4 1 Methanol unter Zugabe von ca. 1 g Kohle wurde a-(2,4-Diamino-5-pyrimidinyl)-2,6- dimethoxy-p-toluylsäuremethylester vom Smp. 250-251 C erhalten.
The present invention relates to a process for the preparation of new benzylpyrimidines of the general formula
EMI1.1
where R1 and R2 are C1-alkyl or r-alkenyl,
Z represents an oxygen atom bonded to one of the ring nitrogen atoms and n = 0 or 1 and of acid addition salts of such compounds.
Examples of C4-alkyl radicals, which can be straight-chain or branched, are methyl, ethyl and propyl. An example of a C2¯3 alkenyl group is allyl.
A subgroup of compounds of the formula I which is particularly preferred in the context of the present invention are those in which R1 and R2 are alkyl, in particular methyl or ethyl.
The benzylpyrimidines of the formula I and their salts are obtained according to the invention by adding a compound of the formula
EMI1.2
in which R3 represents an alkyl group and Rt, R2, Z and n have the meanings given above, the alkoxycarbonyl group reduces to the hydroxymethyl group and, if appropriate, converts a base obtained into an acid addition salt.
The reduction of an alkoxycarbonyl group to the hydroxymethyl group can be carried out with diisobutylaluminum hydride in dioxane.
Unless they are known or are not described below, the starting materials can be prepared in analogy to the methods given below.
For the production of acid addition salts, in particular salts which can be used in pharmaceutical preparations, the inorganic acids usually used for this purpose, such as hydrochloric acid, sulfuric acid, phosphoric acid, etc. or organic acids, such as formic acid, acetic acid, succinic acid, lactic acid, citric acid, maleic acid, fumaric acid, are used , Tartaric acid, methanesulfonic acid, p-toluenesulfonic acid, etc. into consideration.
The compounds of the formula I and their salts have an antibacterial effect. They inhibit the bacterial dihydrofolate reductase and potentiate the antibacterial effect of sulfonamides, such as B. sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulfanilamido-5,6-dimethoxy-pyrimidine, 2 sulfanilamido-4,5-dimethyl-pyrimidine or sulfachinoxaline, sulfadiazine, sulfamonomethoxine, isosulfisoxazole and other inhibitors of enzymes involved in folic acid synthesis such as B. pteridine derivatives.
For such combinations of one or more of the compounds I according to the invention with sulfonamides, oral, rectal and parenteral administration is possible in human medicine. The ratio of compound I to sulfonamide can vary within a wide range; it is z. B. between 1:40 (parts by weight) and 5: 1 (parts by weight); preferred ratios are 1: 1 to 1: 5.
So z. B. a tablet 80 mg of a compound I according to the invention and 400 mg sulfamethoxazole, a children's tablet 20 mg of a compound I according to the invention and 100 mg sulfamethoxazole; Syrup (per 5 ml) contain 40 mg of compound I and 200 mg of sulfamethoxazole.
example
To a solution of 4.45 g of a- (2,4-diamino-5-pyrimidinyl) 2,6-dimethoxy-p-toluic acid methyl ester in 400 ml of abs. Dioxane was added dropwise to 135 ml of approx. 15% diisobutylaluminum hydride solution in dioxane under nitrogen and with exclusion of moisture over the course of 30 minutes. The resulting suspension was stirred at 50 ° C. for 1 hour. After cooling to 30 ° C., a mixture of 25 ml of methanol, 5 ml of water and 50 ml of dioxane was added as the reaction mixture, and the mixture was stirred at 50 ° C. for a further 2 hours. The solid material was separated and discarded. The filtrate was evaporated to dryness.
After recrystallization from approx. 20 ml of methanol, the residue gave 4 - [(2,4-diamino-5-pyrimidinyl) methyl] -2,6-dimethoxybenzyl alcohol of melting point.
227-228 "C.
The raw material was produced as follows:
A mixture of 271 g of 2,6-dimethoxyterephthalic acid 1-mono-methyl ester, 1.2 l abs. Benzene, 100 ml of thionyl chloride and 30 ml of dimethylformamide were refluxed for 2 hours with exclusion of moisture. The solution was evaporated to dryness in vacuo and the residue was dissolved twice in approx. 100 ml abs. Benzene dissolved and the solvent removed again in vacuo. After recrystallization from 7 l of hot n-heptane, the residue gave 260 g of acid chloride with a melting point of 100-101 C. After concentrating the mother liquors, a further 20 g of acid chloride (melting point 90-95 ° C.) were obtained.
40 g of acid chloride were dissolved in 400 ml of xylene dried over sodium. While gassing with N2, 4 g of 5% Pd / BaSO4 and 0.4 ml of quinoline-sulfur regulator were added, the suspension was blown out with N2 for a further 10 minutes and then hydrogen was passed through at 110 ° C. with stirring. The course of the reaction was followed by titrating the HCl formed. After about 2 hours (90% of the theoretical amount of HCl released) the reaction was terminated, the suspension was cooled under N2 and the catalyst was suction filtered. The filtrate was concentrated to dryness in vacuo, the residue was taken up in 150 ml of benzene and shaken with 500 ml of about 37% sodium bisulfite solution for 2 hours. The benzene phase was separated off and the aqueous phase was washed with 100 ml of benzene.
The remaining aqueous solution was cooled to 5 "C and then with approx. 20% NaOH solution to approx.
pH 10 set. The precipitated aldehyde (and inorganic salts) was filtered off with suction. The solid material was taken up in 400 ml of benzene and 700 ml of water, the benzene solution was separated off and the aqueous phase was extracted twice with 100 ml of benzene each time. The combined benzene extracts were washed with 2 × 50 ml of water, dried over MgSO4 and evaporated to dryness in vacuo; 2,6-Dimethoxy-4-formylbenzoic acid methyl ester, m.p. 113-114 "C.
From a solution of 0.9 g of sodium metal in 15 ml of abs.
MeOH, the solvent was evaporated off under N2 and with exclusion of moisture. The remaining sodium methylate was suspended in a solution of 25.2 g of β-morpholinopropionitrile in 28 ml of dimethyl sulfoxide dried over molecular sieves and heated to 70.degree. C. At this temperature, a solution of 30 g of methyl 2,6-dimethoxy-4formylbenzoate in 45 ml of anhydrous dimethyl sulfoxide was added dropwise over the course of 30 minutes and the mixture was then stirred at 75 ° C. for a further 30 minutes. After this time, practically no more aldehyde could be detected. The solution was cooled to + 5 ° C., about 30-40 ml of water were added dropwise, the mixture was seeded and stirring was continued for about 3 hours.
The crystalline product was filtered off with suction, washed with about 15 ml of methanol cooled to 0 C and recrystallized from methanol.
The 4- (2-cyano-3-morpholinoallyl) -2,6-dimethoxybenzoic acid methyl ester has a melting point of 137-138 C.
8.6 g of aniline were concentrated with 7.6 ml with cooling. HC1 offset. 32 g of methyl 4- (2-cyano-3-morpholino allyl) -2,6-dimethoxybenzoate and 100 ml of isopropanol were then added. The suspension was heated to reflux with stirring for 30 minutes. About 1/3 to half of the solvent was evaporated, 20 ml of water were added, the crystalline product filtered off with suction, washed with a little cold methanol and dried. Recrystallization from methanol gave 4- (3-anilino-2-cyanoallyl) -2,6-dimethoxybenzoic acid methyl ester of melting point 193-194 C.
In a 2 l flask with magnetic stirrer and reflux condenser, 8 g of Na metal in 200 ml of abs. Dissolved methanol.
24.7 g of guanidine HCl were added to this solution and the suspension was stirred at room temperature for 30 minutes. The sodium chloride was sucked off and mixed with approx.
10 ml cold abs. Methanol washed. The filtrate was admixed with 46 g of 4- (3-anilino-2-cyanoallyl) -2,6-dimethoxybenzoic acid methyl ester and 1000 ml of isopropanol and the suspension was refluxed for 50 hours while stirring. The reaction mixture was concentrated and cooled, and the precipitated crystals were suction filtered.
After crystallization from about 4 liters of methanol with the addition of about 1 g of charcoal, methyl a- (2,4-diamino-5-pyrimidinyl) -2,6-dimethoxy-p-toluic acid with a melting point of 250-251 ° C. was obtained.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH742676A CH596191A5 (en) | 1974-06-21 | 1974-06-21 | Anti-bacterial benzyl-pyrimidines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH742676A CH596191A5 (en) | 1974-06-21 | 1974-06-21 | Anti-bacterial benzyl-pyrimidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH596191A5 true CH596191A5 (en) | 1978-03-15 |
Family
ID=4324944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH742676A CH596191A5 (en) | 1974-06-21 | 1974-06-21 | Anti-bacterial benzyl-pyrimidines |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH596191A5 (en) |
-
1974
- 1974-06-21 CH CH742676A patent/CH596191A5/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH642965A5 (en) | SUBSTITUTED 5- (2-IMIDAZOLIN-2-YL) AMINOPYRIMIDINE AND METHOD FOR THE PRODUCTION THEREOF. | |
| EP0122580B1 (en) | Pyrimidine derivatives, their preparation and pharmaceutical compositions | |
| DE2849537A1 (en) | SUBSTITUTED 5- (2-IMIDAZOLIN-2-YL) AMINOPYRIMIDINE AND METHOD FOR PRODUCING THE SAME | |
| DE2443682C2 (en) | New 2,4-diamino-5-benzylpyrimidines | |
| DE2452889C2 (en) | New benzylpyrimidines, processes for their preparation and pharmaceuticals containing them | |
| CH596191A5 (en) | Anti-bacterial benzyl-pyrimidines | |
| CH591457A5 (en) | ||
| DE2903850A1 (en) | 2-AMINO-8-CYCLOPROPYL-5-OXO-5,8- DIHYDRO-PYRIDO CORNER CLAMP ON 2,3-D CORNER CLAMP FOR -PYRIMIDINE-6-CARNONIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| DE671787C (en) | Process for the preparation of pyrimidine compounds | |
| CH589066A5 (en) | Anti-bacterial benzyl-pyrimidines - esp powerful in combination with sulphonamides | |
| AT351033B (en) | PROCESS FOR THE PRODUCTION OF NEW BENZYL PYRIMIDINES AND THEIR SALT | |
| DE2937023A1 (en) | Substd. 5-(2-imidazolin-2-yl)-amino-pyrimidine(s) - useful for treatment of hypertension | |
| WO1996002540A1 (en) | Heterocyclyl-1-phenyl substituted quinolone carboxylic acids as antiviral agents | |
| DE2558150A1 (en) | NEW BENZYL PYRIMIDINE | |
| AT229870B (en) | Process for the preparation of sulfonamides of the pyrimidine series | |
| AT256863B (en) | Process for the preparation of new basic derivatives of dihydro-1, 3-benzoxazine-2, 4-dione | |
| DE2546667A1 (en) | NEW 2,4-DIAMINO-5-BENZYLPYRIMIDINE, THE METHOD OF MANUFACTURING THEM AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| CH405322A (en) | Process for the preparation of new sulfonamides of the pyrimidine series | |
| AT244344B (en) | Process for the preparation of new pyrimidine compounds | |
| AT228209B (en) | Process for the production of new sulfonamides | |
| CH605829A5 (en) | Sulphonamide-potentiating benzyl-pyrimidines | |
| AT360547B (en) | METHOD FOR PRODUCING NEW 2,4- DIAMINO-5-BENZYLPYRIMIDINES AND THEIR SALTS | |
| AT253496B (en) | Process for the preparation of new dihydrothieno [3, 2-d] pyrimidines | |
| DE2755638A1 (en) | INTERMEDIATE PRODUCT FOR THE PRODUCTION OF BLOOD PRESSURE-REDUCING 6,7-DIMETHOXY- 4-AMINO-2-CORNER CLAMP ON 4- (2-FUROYL) - 1-PIPERAZINYL CORNER CLAMP ON CHINAZOLINE | |
| CH589064A5 (en) | Anti-bacterial benzyl-pyrimidines - esp powerful in combination with sulphonamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |